ACADIA Pharmaceuticals Inc. and Meiji Seika Kaisha Ltd. announced in April their collaboration to develop and commercialize a novel class of pro-cognitive drugs called PCAPs to treat patients with schizophrenia and related disorders.
A group of Canadian researchers has pinpointed a common virus that could provide a new and effective approach to eliminating breast cancer stem cells—a key tool in the battle against the deadly disease.
A new presidential administration and a new Congress—not to mention the ever-changing economic situation on Wall Street and in financial centers around the world—are testing the speed at which biotechnology companies can react and adapt to the evolving environment.
Last month, I headed to Denver with the rest of my DDN colleagues to attend the AACR's 100th Annual Meeting, eager to learn about the latest developments in oncology research. But during my last few hours in Denver, my bubble of optimism was pricked by deflating reality.